Overview

A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

Status:
Terminated

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ERCC1(excision repair cross-complementation 1 ) expression has effects on platinum-based chemotherapy for patients with locally advanced or metastatic gastric cancer, and to explore if ERCC1 can act as a biological predictor for the individual therapy of gastric cancer

Phase:

Phase 2

Details

Lead Sponsor:

China Medical University, China

Treatments:

Capecitabine
Cisplatin
Docetaxel